Smith Group Asset Management’s BridgeBio Pharma BBIO Stock Holding History

Smith Group Asset Management’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-100	Closed	-$2K	–	283
2021 Q4	$2K	Hold	100	–	–	﹤0.01%	359
2021 Q3	$5K	Hold	100	–	–	﹤0.01%	346
2021 Q2	$6K	Hold	100	–	–	﹤0.01%	335
2021 Q1	$6K	Sell	100 -2,890	-97%	-$189K	﹤0.01%	297
2020 Q4	$213K	Sell	2,990 -10	-0.3%	-$482	0.01%	178
2020 Q3	$113K	Buy	+3,000	New	+$94.4K	0.01%	193

Other funds holding BBIO

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

AIG

American International Group New York $609M AUM 23.67% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Smith Group Asset Management's BBIO Position: Q1 2022 in Review

Smith Group Asset Management sold out of BridgeBio Pharma (BBIO) in Q1 2022, closing a stake of 100 shares — an estimated $2K sold.

Smith Group Asset Management first reported a position in BBIO in Q3 2020 and held it in 6 quarters. The position peaked at $213K in Q4 2020. 178 funds tracked by Wall St. Rank hold BBIO as of Q1 2022.

Smith Group Asset Management reported no remaining BridgeBio Pharma position as of Q1 2022 after selling out during the quarter.
Smith Group Asset Management sold 100 BridgeBio Pharma shares in Q1 2022, an estimated $2K.
Smith Group Asset Management first reported a position in BridgeBio Pharma in Q3 2020 and held it in 6 quarters.
Smith Group Asset Management's BridgeBio Pharma position peaked at $213K in Q4 2020.
178 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2022.

Based on Smith Group Asset Management's 13F filing for Q1 2022, filed 5 May 2022.